about
Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial.Radiation induced coronary heart disease.Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial.Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).Delivery of non-surgical oncology care.Chemoradiation schedules--what radiotherapy?Adjuvant radiation therapy for rectal cancer: selecting the right cases.NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.The use of radiotherapy in rectal cancer.Treatment of T4 tumours: the role of radiotherapy.Systematic Review of Radiation Therapy Toxicity Reporting in Randomized Controlled Trials of Rectal Cancer: A Comparison of Patient-Reported Outcomes and Clinician Toxicity Reporting.Systematic review of the quality of life issues associated with anal cancer and its treatment with radiochemotherapy.30 day mortality in adult palliative radiotherapy--A retrospective population based study of 14,972 treatment episodes.A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.An evaluation of four CT-MRI co-registration techniques for radiotherapy treatment planning of prone rectal cancer patientsThe integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?Developments in the use of chemoradiotherapy in rectal cancer.Sphincter saving is the primary objective for local treatment of cancer of the lower rectum.A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer.A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) studyEffective treatment of anal cancer in the elderly with low-dose chemoradiotherapyClarifying the TNM staging of rectal cancer in the context of modern imaging and neo-adjuvant treatment: 'y''u' and 'p' need 'mr' and 'ct'.Wide Variation in the Use of Radiotherapy in the Management of Surgically Treated Rectal Cancer Across the English National Health Service.Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost.Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer.The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stageMultidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2).Biomarkers in anal cancer: from biological understanding to stratified treatment.High hospital research participation and improved colorectal cancer survival outcomes: a population-based study.Initial Results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015.Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma.Defunctioning stomas prior to chemoradiation for anal cancer are usually permanent.Adenocarcinoma of the anal canal - a systematic review.Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic.Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.Prevention and Management of Radiation-induced Late Gastrointestinal Toxicity.Radiotherapy for rectal cancer: Short course versus long course - When and how.
P50
Q33415864-06BFEF47-CE1E-479D-BF0A-ED1B82A5B61DQ33612903-0BBA4EBB-CD5D-49DC-98B9-C3B7423EF69FQ33618792-674E3902-272B-43B3-9815-B65021A20BDCQ33783068-06A8246B-CE85-46A4-A127-6938B1F9B641Q33808952-E15DCED6-B964-4D33-9BA3-F94066F34FD7Q34501938-37FD916E-D4C4-4A1C-83C0-33C07A72AF58Q35060471-818A4642-E5C0-44E1-ACDF-FC84D0AB30FEQ35085650-941A9E10-BD29-49CA-A12E-DFCB9A9210FFQ35111178-B27736BD-EEA0-4CC7-BCA7-8918A1C156D4Q35202158-ACFF5AEC-7835-4B61-A123-BBE107E37B9EQ35661915-136A35A0-601D-40BA-8B68-E8F8541941ADQ35750692-CA99EA30-04D8-4027-B3A3-D2ADC1049A17Q35856616-C72ED556-FB04-41CF-B458-EDF1F73F3833Q36130588-4B2D91AA-CA2D-4762-A079-30638B3ED52FQ36325514-DC454C16-50FD-4D66-B25F-73035E7ADBCCQ36406297-C064663D-A05D-4930-A6A0-14AD6D182230Q36524367-6608DB40-97F1-423B-829E-8B14B20B6E01Q36583077-C79B72BE-8390-4A2D-8EE3-2990274F7678Q36609922-4D5C903F-6B86-40B7-9174-FEF358866465Q36610647-6CC34A61-B8CD-46D0-A670-3DF47498C447Q36615549-42C9F5C8-64A4-4C3A-9B7B-93A3EE5C5927Q36616658-1B66181E-16E5-4680-A5A8-D2A5D308168BQ36820078-FB66C0DE-8577-4FFF-8C7B-19564802E98FQ37094342-6F4E5D66-792C-4BAE-9222-EA19BE68CC9DQ37158196-908529B1-5A15-4BD5-8216-1DF9A87EAB6DQ37340391-BB958A19-E3A5-4960-8208-67295595DAF5Q37401414-8BDADBE6-D29C-43E8-AE5F-9383DEC5D4F3Q37497743-759732EC-3436-4225-8918-EFBC9F374575Q37549037-4F61D07E-6D63-4312-9EA7-9E0117BB5549Q37592879-C0A9D2E3-733A-4AA8-8AA8-B463A011C31CQ37600075-8884BA39-FF60-42B3-9909-BE0A375E6167Q37638312-B98850C9-805D-411F-BAC2-2B51056468ECQ37681208-6D85F95A-DB40-46C9-804C-86F2E3CE8AE9Q37686867-DF34379E-2BC2-4B82-800B-2AE4974D2F0BQ37813183-75BFF22D-D68A-49EB-90AB-52D8A3A183F4Q38117863-9A65BD84-FF68-40CF-BB38-ECA332047543Q38275384-91F21133-BB4A-4E7E-85AA-527D9B0E5F68Q38432466-98B74571-6AF6-4C72-ACC8-AD12FFC6AF42Q38541010-826702DE-B862-4C75-B579-32D4080C7C57Q38555910-1E559782-93E5-4B92-B3DC-E436ECEA1FEC
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David Sebag-Montefiore
@ast
David Sebag-Montefiore
@en
David Sebag-Montefiore
@es
David Sebag-Montefiore
@nl
David Sebag-Montefiore
@sl
type
label
David Sebag-Montefiore
@ast
David Sebag-Montefiore
@en
David Sebag-Montefiore
@es
David Sebag-Montefiore
@nl
David Sebag-Montefiore
@sl
prefLabel
David Sebag-Montefiore
@ast
David Sebag-Montefiore
@en
David Sebag-Montefiore
@es
David Sebag-Montefiore
@nl
David Sebag-Montefiore
@sl
P106
P1153
6701695217
P2031
1989-01-01T00:00:00Z
P21
P31
P496
0000-0002-5978-9259